#$SVRA +3.7% [Savara’s MOLBREEVI just got FDA Priority Review for autoimmune PAP. Possible U.S. approval in August 2026 and first-ever approved therapy in US & Europe.] notreload.xyz/fda-grants-p...
FDA Grants Priority Review to MOLBREEVI for Autoimmune PAP
Savara’s MOLBREEVI just got FDA Priority Review for autoimmune PAP. Possible U.S. approval in August 2026 and first-ever approved therapy in US & Europe.
notreload.xyz
February 20, 2026 at 10:22 PM
#$SVRA +3.7% [Savara’s MOLBREEVI just got FDA Priority Review for autoimmune PAP. Possible U.S. approval in August 2026 and first-ever approved therapy in US & Europe.] notreload.xyz/fda-grants-p...
Savara (#$SVRA): MOLBREEVI FDA Target Action Date Set for November 22
Free Biotech Catalyst Calendar on Merlintrader.
www.merlintrader.com/savara-svra-...
Free Biotech Catalyst Calendar on Merlintrader.
www.merlintrader.com/savara-svra-...
September 23, 2026 at 8:11 PM
Savara (#$SVRA): MOLBREEVI FDA Target Action Date Set for November 22
Free Biotech Catalyst Calendar on Merlintrader.
www.merlintrader.com/savara-svra-...
Free Biotech Catalyst Calendar on Merlintrader.
www.merlintrader.com/savara-svra-...
Savara ($SVRA): What Does ERS Encore Add Before the FDA Review?
https://www.merlintrader.com/savara-svra-stock-hub-2026/
https://www.merlintrader.com/savara-svra-stock-hub-2026/
Savara ($SVRA) Stock Hub: ERS Encore, November FDA Review And Conditional Funding
Savara’s September 6 ERS sessions reprise previously presented IMPALA-2 findings. The next FDA target remains November 22 for investigational MOLBREEVI. Positive pivotal evidence sits alongside review and launch risk, $173 million of June liquidity and up to $150 million of funding subject to approval and contractual terms.
www.merlintrader.com
September 5, 2026 at 9:53 AM
Savara ($SVRA): What Does ERS Encore Add Before the FDA Review?
https://www.merlintrader.com/savara-svra-stock-hub-2026/
https://www.merlintrader.com/savara-svra-stock-hub-2026/
#SVRA Savara Reports Second Quarter 2026 Financial Results and Provides Business Update
https://www.stocktitan.net/news/SVRA/savara-reports-second-quarter-2026-financial-results-and-provides-99l5qbbk51rc.html
https://www.stocktitan.net/news/SVRA/savara-reports-second-quarter-2026-financial-results-and-provides-99l5qbbk51rc.html
Savara's inhaled MOLBREEVI faces FDA decision Nov. 22
Savara had ~$173M in cash and investments at June 30, plus up to ~$150M upon FDA approval. EMA and U.K. decisions are expected in 2027 and 2026.
www.stocktitan.net
August 11, 2026 at 8:05 PM
#SVRA Savara Reports Second Quarter 2026 Financial Results and Provides Business Update
https://www.stocktitan.net/news/SVRA/savara-reports-second-quarter-2026-financial-results-and-provides-99l5qbbk51rc.html
https://www.stocktitan.net/news/SVRA/savara-reports-second-quarter-2026-financial-results-and-provides-99l5qbbk51rc.html
Savara refiled MOLBREEVI BLA after FDA rejection, raised $140M, granted Priority Review
$SVRA 10-K → https://filingdiff.com/ticker/SVRA/0001193125-26-105076/
$SVRA 10-K → https://filingdiff.com/ticker/SVRA/0001193125-26-105076/
June 9, 2026 at 8:10 PM
Savara refiled MOLBREEVI BLA after FDA rejection, raised $140M, granted Priority Review
$SVRA 10-K → https://filingdiff.com/ticker/SVRA/0001193125-26-105076/
$SVRA 10-K → https://filingdiff.com/ticker/SVRA/0001193125-26-105076/
$SVRA -29.2% [Savara, a company specializing in rare respiratory illnesses, disclosed that the FDA rejected their application for MOLBREEVI, a potential therapy for Autoimmune Pulmonary Alveolar Proteinosis (autoimmune PAP).] t.co/MNsbKV0nIA
https://investors.savarapharma.com/news/news-details/2025/Savara-Receives-Refusal-to-File-RTF-Letter-From-the-U-S--Food-and-Drug-Administration-FDA-for-the-Biologics-License-Application-BLA-for-MOLBRE...
t.co
May 27, 2025 at 2:07 PM
$SVRA -29.2% [Savara, a company specializing in rare respiratory illnesses, disclosed that the FDA rejected their application for MOLBREEVI, a potential therapy for Autoimmune Pulmonary Alveolar Proteinosis (autoimmune PAP).] t.co/MNsbKV0nIA
NEWS: Savara shares plunge after the FDA rejects its filing for lead drug Molbreevi, but is the reaction overblown?
pharmaphorum.com/news/manufac...
pharmaphorum.com/news/manufac...
May 28, 2025 at 12:52 PM
NEWS: Savara shares plunge after the FDA rejects its filing for lead drug Molbreevi, but is the reaction overblown?
pharmaphorum.com/news/manufac...
pharmaphorum.com/news/manufac...
How Investors May Respond To Savara (SVRA) Joining S&P Biotech Index After Key MOLBREEVI Patent Win - simplywall.st: How Investors May Respond To Savara (SVRA) Joining S&P Biotech Index After Key MOLBREEVI Patent Win simplywall.st
How Investors May Respond To Savara (SVRA) Joining S&P Biotech Index After Key MOLBREEVI Patent Win - simplywall.st
How Investors May Respond To Savara (SVRA) Joining S&P Biotech Index After Key MOLBREEVI Patent Win simplywall.st
news.google.com
December 23, 2025 at 6:48 AM
How Investors May Respond To Savara (SVRA) Joining S&P Biotech Index After Key MOLBREEVI Patent Win - simplywall.st: How Investors May Respond To Savara (SVRA) Joining S&P Biotech Index After Key MOLBREEVI Patent Win simplywall.st
Savara (SVRA): Valuation Check After European Patent Win for MOLBREEVI in Autoimmune PAP - simplywall.st: Savara (SVRA): Valuation Check After European Patent Win for MOLBREEVI in Autoimmune PAP simplywall.st
Savara (SVRA): Valuation Check After European Patent Win for MOLBREEVI in Autoimmune PAP - simplywall.st
Savara (SVRA): Valuation Check After European Patent Win for MOLBREEVI in Autoimmune PAP simplywall.st
news.google.com
December 15, 2025 at 5:24 AM
Savara (SVRA): Valuation Check After European Patent Win for MOLBREEVI in Autoimmune PAP - simplywall.st: Savara (SVRA): Valuation Check After European Patent Win for MOLBREEVI in Autoimmune PAP simplywall.st
Savara Announces European Patent Office (EPO) Intends to Grant a Patent for the Liquid Formulation of MOLBREEVI - BioSpace: Savara Announces European Patent Office (EPO) Intends to Grant a Patent for the Liquid Formulation of MOLBREEVI BioSpace
Savara Announces European Patent Office (EPO) Intends to Grant a Patent for the Liquid Formulation of MOLBREEVI - BioSpace
Savara Announces European Patent Office (EPO) Intends to Grant a Patent for the Liquid Formulation of MOLBREEVI BioSpace
news.google.com
December 12, 2025 at 1:03 PM
Savara Announces European Patent Office (EPO) Intends to Grant a Patent for the Liquid Formulation of MOLBREEVI - BioSpace: Savara Announces European Patent Office (EPO) Intends to Grant a Patent for the Liquid Formulation of MOLBREEVI BioSpace
Savara (SVRA) Is Up 8.9% After European Patent Boost For MOLBREEVI Nebulized Therapy - simplywall.st: Savara (SVRA) Is Up 8.9% After European Patent Boost For MOLBREEVI Nebulized Therapy simplywall.st
Savara (SVRA) Is Up 8.9% After European Patent Boost For MOLBREEVI Nebulized Therapy - simplywall.st
Savara (SVRA) Is Up 8.9% After European Patent Boost For MOLBREEVI Nebulized Therapy simplywall.st
news.google.com
December 12, 2025 at 12:56 AM
Savara (SVRA) Is Up 8.9% After European Patent Boost For MOLBREEVI Nebulized Therapy - simplywall.st: Savara (SVRA) Is Up 8.9% After European Patent Boost For MOLBREEVI Nebulized Therapy simplywall.st
Savara (SVRA) Deepens Patent Moat for MOLBREEVI in Europe Is Its Rare-Disease Edge Widening? - Yahoo Finance: Savara (SVRA) Deepens Patent Moat for MOLBREEVI in Europe Is Its Rare-Disease Edge Widening? Yahoo Finance
Savara (SVRA) Deepens Patent Moat for MOLBREEVI in Europe Is Its Rare-Disease Edge Widening? - Yahoo Finance
Savara (SVRA) Deepens Patent Moat for MOLBREEVI in Europe Is Its Rare-Disease Edge Widening? Yahoo Finance
news.google.com
December 11, 2025 at 11:47 PM
Savara (SVRA) Deepens Patent Moat for MOLBREEVI in Europe Is Its Rare-Disease Edge Widening? - Yahoo Finance: Savara (SVRA) Deepens Patent Moat for MOLBREEVI in Europe Is Its Rare-Disease Edge Widening? Yahoo Finance
Savara (Nasdaq: SVRA) poised for EPO MOLBREEVI liquid patent, EU rights to March 2041 - Stock Titan: Savara (Nasdaq: SVRA) poised for EPO MOLBREEVI liquid patent, EU rights to March 2041 Stock Titan
Savara (Nasdaq: SVRA) poised for EPO MOLBREEVI liquid patent, EU rights to March 2041 - Stock Titan
Savara (Nasdaq: SVRA) poised for EPO MOLBREEVI liquid patent, EU rights to March 2041 Stock Titan
news.google.com
December 11, 2025 at 1:12 PM
Savara (Nasdaq: SVRA) poised for EPO MOLBREEVI liquid patent, EU rights to March 2041 - Stock Titan: Savara (Nasdaq: SVRA) poised for EPO MOLBREEVI liquid patent, EU rights to March 2041 Stock Titan
Savara Announces European Patent Office (EPO) Intends to Grant a Patent for the Liquid Formulation of MOLBREEVI* - Business Wire: Savara Announces European Patent Office (EPO) Intends to Grant a Patent for the Liquid Formulation of MOLBREEVI* Business Wire
Savara Announces European Patent Office (EPO) Intends to Grant a Patent for the Liquid Formulation of MOLBREEVI* - Business Wire
Savara Announces European Patent Office (EPO) Intends to Grant a Patent for the Liquid Formulation of MOLBREEVI* Business Wire
news.google.com
December 11, 2025 at 1:07 PM
Savara Announces European Patent Office (EPO) Intends to Grant a Patent for the Liquid Formulation of MOLBREEVI* - Business Wire: Savara Announces European Patent Office (EPO) Intends to Grant a Patent for the Liquid Formulation of MOLBREEVI* Business Wire
Savara and PARI Granted a European Patent Covering the Drug-Device Combination of MOLBREEVI* Deliver - PharmiWeb.com: Savara and PARI Granted a European Patent Covering the Drug-Device Combination of MOLBREEVI* Deliver PharmiWeb.com
Savara and PARI Granted a European Patent Covering the Drug-Device Combination of MOLBREEVI* Deliver - PharmiWeb.com
Savara and PARI Granted a European Patent Covering the Drug-Device Combination of MOLBREEVI* Deliver PharmiWeb.com
news.google.com
December 2, 2025 at 4:27 PM
Savara and PARI Granted a European Patent Covering the Drug-Device Combination of MOLBREEVI* Deliver - PharmiWeb.com: Savara and PARI Granted a European Patent Covering the Drug-Device Combination of MOLBREEVI* Deliver PharmiWeb.com
Savara (Nasdaq: SVRA) granted European patent for MOLBREEVI device combo in autoimmune PAP - Stock Titan: Savara (Nasdaq: SVRA) granted European patent for MOLBREEVI device combo in autoimmune PAP Stock Titan
Savara (Nasdaq: SVRA) granted European patent for MOLBREEVI device combo in autoimmune PAP - Stock Titan
Savara (Nasdaq: SVRA) granted European patent for MOLBREEVI device combo in autoimmune PAP Stock Titan
news.google.com
December 2, 2025 at 1:09 PM
Savara (Nasdaq: SVRA) granted European patent for MOLBREEVI device combo in autoimmune PAP - Stock Titan: Savara (Nasdaq: SVRA) granted European patent for MOLBREEVI device combo in autoimmune PAP Stock Titan